Protagonist Therapeutics Inc (NASDAQ:PTGX) Sees Large Decline in Short Interest

Share on StockTwits

Protagonist Therapeutics Inc (NASDAQ:PTGX) was the target of a large drop in short interest in October. As of October 31st, there was short interest totalling 1,050,000 shares, a drop of 5.4% from the September 30th total of 1,110,000 shares. Based on an average trading volume of 203,900 shares, the short-interest ratio is currently 5.1 days. Currently, 5.2% of the shares of the stock are short sold.

Several analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 14th. Svb Leerink reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research report on Tuesday, August 13th. Nomura reiterated a “buy” rating and set a $29.00 price target on shares of Protagonist Therapeutics in a research report on Sunday, August 11th. HC Wainwright set a $23.00 price target on shares of Protagonist Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, BidaskClub lowered shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $19.60.

NASDAQ PTGX opened at $10.20 on Tuesday. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $293.83 million, a price-to-earnings ratio of -5.86 and a beta of 1.74. The firm’s 50 day simple moving average is $11.71 and its 200 day simple moving average is $11.90. Protagonist Therapeutics has a 1 year low of $5.49 and a 1 year high of $16.67.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.10. The business had revenue of $4.14 million for the quarter, compared to analyst estimates of $5.75 million. Protagonist Therapeutics had a negative net margin of 209.02% and a negative return on equity of 74.86%. On average, equities research analysts forecast that Protagonist Therapeutics will post -2.99 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of PTGX. BlackRock Inc. boosted its position in Protagonist Therapeutics by 271.6% in the second quarter. BlackRock Inc. now owns 1,017,421 shares of the company’s stock valued at $12,321,000 after buying an additional 743,632 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Protagonist Therapeutics by 99.1% in the second quarter. JPMorgan Chase & Co. now owns 558,729 shares of the company’s stock valued at $6,693,000 after buying an additional 278,066 shares in the last quarter. VHCP Management III LLC boosted its position in Protagonist Therapeutics by 32.5% in the second quarter. VHCP Management III LLC now owns 1,072,348 shares of the company’s stock valued at $12,986,000 after buying an additional 263,025 shares in the last quarter. VHCP Management II LLC boosted its position in Protagonist Therapeutics by 57.3% in the second quarter. VHCP Management II LLC now owns 426,781 shares of the company’s stock valued at $5,168,000 after buying an additional 155,404 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its position in Protagonist Therapeutics by 54.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 397,278 shares of the company’s stock valued at $4,811,000 after buying an additional 139,550 shares in the last quarter. Hedge funds and other institutional investors own 71.27% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.

Recommended Story: What is the 52-week high/low?

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.